Fleischmann R, Mysler E, Bessette L, et al. Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. RMD Open 2022;8:e002012. doi: 10.1136/rmdopen-2021-002012
Under the Efficacy heading, the sentence ‘Numerically higher responses for patients who switched from adalimumab to upadacitinib vs those who switched from adalimumab to upadacitinib were also observed’ has been changed to ‘Numerically higher responses for patients who switched from adalimumab to upadacitinib vs those who switched from upadacitinib to adalimumab were also observed’.